Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Holloway RW, Thaker P, Mendivil AA, et al. A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer Int J Gynecol Cancer 2023; 33: 1458-1463.
This article has been corrected since it was first published, to correct author name ‘Ramez Eskander’.